BJO

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER


[Advanced]
Published Online First: 6 July 2006. doi:10.1136/bjo.2006.094326
British Journal of Ophthalmology 2006;90:1370-1373
Copyright © 2006 by the BMJ Publishing Group Ltd.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
bjo.2006.094326v1
90/11/1370    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cantor, L B
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cantor, L B
Topic Collections
Right arrowRelated Article

EXTENDED REPORT

Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension

L B Cantor, J Hoop, L Morgan, D WuDunn, Y Catoira The Bimatoprost–Travoprost Study Group

Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, Indiana, USA

Correspondence to:
Correspondence to:
L B Cantor
Department of Ophthalmology, Indiana University Medical Center, 702 Rotary Circle, Indianapolis, IN 46202, USA;lcantor{at}iupui.edu

Aim: To evaluate the efficacies of bimatoprost and travoprost for lowering of intraocular pressure (IOP) for the treatment of glaucoma and ocular hypertension.

Methods: Prospective, randomised, investigator-blinded, parallel-group clinical trial. After completing a washout of all glaucoma drugs, patients (n = 157) were randomised to bimatoprost or travoprost for 6 months. Visits were at baseline, 1 week, and 1, 3 and 6 months. IOP was measured at 09:00 h at each visit and also at 13:00 and 16:00 h at baseline and at 3 and 6 months.

Results: No significant between-group differences were observed in IOP at baseline, at 09:00, 13:00 or 16:00 h (p>=0.741). After 6 months, both drugs significantly reduced IOP at every time point (p<=0.001). After 6 months, mean IOP reduction at 09:00 h was 7.1 mm Hg (27.9%) with bimatoprost (n = 76) and 5.7 mm Hg (23.3%) with travoprost (n = 81; p = 0.014). At 13:00 h, mean IOP reduction was 5.9 mm Hg with bimatoprost (25.3%) and 5.2 mm Hg (22.4%) with travoprost (p = 0.213). At 16:00 h, the mean IOP reduction was 5.3 mm Hg (22.5%) with bimatoprost and 4.5 mm Hg (18.9%; p = 0.207) with travoprost. Both study drugs were well tolerated, with ocular redness the most commonly reported adverse event in both treatment groups.

Conclusions: Bimatoprost provided greater mean IOP reductions than travoprost.

Abbreviations: IOP, intraocular pressure; OAG, open-angle glaucoma; OHT, ocular hypertension


Related Article

Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension
R Noecker
Br. J. Ophthalmol. 2006 90: 1336-1337. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
 Br. J. Ophthalmol.Home page
L B Cantor
Author's reply
Br. J. Ophthalmol., June 1, 2008; 92(6): 863 - 864.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2006 by the BMJ Publishing Group Ltd.